October 15, 2010
The makers of the miracle toxin that erases frown lines by paralyzing facial muscles won the Food and Drug Administration's blessing on Friday to market Botox for the prevention of chronic migraine headaches. The FDA's decision expands the potential market for Botox, which burst upon the American cosmetic scene in the late 1980s, to 12% of the U.S. population -- the proportion of Americans thought to suffer from the throbbing, pulsating pain of migraine headaches . The agency's approval Friday allows Allergan Inc., which produces a purified version of the botulinum toxin, to advertise to consumers and promote to doctors the use of Botox for chronic migraine, defined as migraine headaches that occur more than 14 days per month.
September 11, 2013 |
It's getting easier for Baby Boomers to hide their years. Federal regulators for the first time have approved Botox injections to temporarily ease the appearance of crow's feet. The Food and Drug Administration on Wednesday approved the drug, made by Irvine-based Allergan Inc., to treat wrinkles that form on the outside edge of the eyes. The decision comes 11 years after the FDA approved Botox for the temporary improvement of wrinkles between the eyebrows, known as frown lines.
September 12, 2008 |
Botox, the botulism-based drug that has wiped wrinkles from the faces of millions, may be approved for another use: stopping headaches. Drug maker Allergan Inc. said Thursday that it had new evidence that its injectable drug could help relieve migraine headaches. Based on preliminary results from two company-funded studies, Allergan said it would ask the Food and Drug Administration to approve Botox for chronic migraine next year. The FDA approved Botox to smooth wrinkles and age lines in 2002, and it has grown into a blockbuster product for Irvine-based Allergan, with $2.1 billion in sales last year.
October 3, 2009 |
Allergan Inc., maker of wrinkle treatment Botox, is challenging the government's ban on marketing off-label uses for pharmaceuticals. In a lawsuit filed Thursday, the Irvine company argued that it should be allowed to give doctors information about using Botox for treatments not approved by the Food and Drug Administration, including bladder problems, muscle spasms and headaches. Botox is approved by the FDA for use cosmetically as a wrinkle treatment and medically for eye-muscle disorders, excessive underarm sweating and cervical dystonia in adults, which causes abnormal head positions and neck pain.
March 5, 2008 |
The U.S. Department of Justice is looking at Allergan Inc.'s promotion of its blockbuster wrinkle drug Botox for medical uses, but investors didn't seem too worried about the news Tuesday. Allergan shares closed at $57.38, down $1.28 or 2.2% on word that the Irvine company received a subpoena from the U.S. Attorney's Office for the Northern District of Georgia demanding documents regarding its promotional and educational practices involving the use of the botulinum toxin-based drug for medical problems.
May 8, 2008 |
Allergan Inc.'s net income more than doubled in the first quarter as sales accelerated outside the U.S. for the wrinkle remover Botox. Demand cooled in the U.S., and the company blamed the economy. Net income increased to $111.4 million, or 36 cents a share, from $43.8 million, or 14 cents, a year earlier, the company said. Revenue grew 23% to $1.08 billion, bolstered by converting overseas sales in other currencies to the dollar. Irvine-based Allergan sells cosmetic and medical products including breast implants, surgical devices to remedy obesity and a treatment for overactive bladders.